155 related articles for article (PubMed ID: 37374179)
1. Anti-Proliferative Effect of Radiotherapy and Implication of Immunotherapy in Anaplastic Thyroid Cancer Cells.
Wächter S; Roth S; Gercke N; Schötz U; Dikomey E; Engenhart-Cabillic R; Maurer E; Bartsch DK; Di Fazio P
Life (Basel); 2023 Jun; 13(6):. PubMed ID: 37374179
[TBL] [Abstract][Full Text] [Related]
2. Synergic Induction of Autophagic Cell Death in Anaplastic Thyroid Carcinoma.
Wächter S; Knauff F; Roth S; Keber C; Holzer K; Manoharan J; Maurer E; Bartsch DK; Di Fazio P
Cancer Invest; 2023 Apr; 41(4):405-421. PubMed ID: 36811581
[TBL] [Abstract][Full Text] [Related]
3. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.
Cantara S; Bertelli E; Occhini R; Regoli M; Brilli L; Pacini F; Castagna MG; Toti P
Endocrine; 2019 Apr; 64(1):122-129. PubMed ID: 30762153
[TBL] [Abstract][Full Text] [Related]
4. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
5. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
6. Response to immunotherapy in a patient with anaplastic thyroid cancer: A case report.
Zheng L; Li L; He Q; Wang M; Ma Y; Zhu J; Li Y; Fu X; Zhang Y
Medicine (Baltimore); 2021 Aug; 100(32):e26138. PubMed ID: 34397868
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic Thyroid Cancer Successfully Treated With Radiation and Immunotherapy: A Case Report.
Yang SR; Tsai MH; Hung CJ; Peng SL; Chiu NT; Huang YH; Tsai HJ
AACE Clin Case Rep; 2021; 7(5):299-302. PubMed ID: 34522768
[TBL] [Abstract][Full Text] [Related]
8. PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN THYROID CANCER.
Zhang GQ; Wei WJ; Song HJ; Sun ZK; Shen CT; Zhang XY; Chen XY; Qiu ZL; Luo QY
Endocr Pract; 2019 Mar; 25(3):279-286. PubMed ID: 30913016
[TBL] [Abstract][Full Text] [Related]
9. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
10. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
Adam P; Kircher S; Sbiera I; Koehler VF; Berg E; Knösel T; Sandner B; Fenske WK; Bläker H; Smaxwil C; Zielke A; Sipos B; Allelein S; Schott M; Dierks C; Spitzweg C; Fassnacht M; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():712107. PubMed ID: 34475850
[TBL] [Abstract][Full Text] [Related]
11. Alantolactone induces concurrent apoptosis and GSDME-dependent pyroptosis of anaplastic thyroid cancer through ROS mitochondria-dependent caspase pathway.
Hu Y; Wen Q; Cai Y; Liu Y; Ma W; Li Q; Song F; Guo Y; Zhu L; Ge J; Zeng Q; Wang J; Yin C; Zheng G; Ge M
Phytomedicine; 2023 Jan; 108():154528. PubMed ID: 36343549
[TBL] [Abstract][Full Text] [Related]
12. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ndishabandi D; Ashry T; McCarthy M; Zhou Z; Amin S; Freeman GJ; Alessandrini A; Parangi S
Br J Cancer; 2018 Nov; 119(10):1223-1232. PubMed ID: 30327563
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy.
Boruah M; Gaddam P; Agarwal S; Mir RA; Gupta R; Sharma MC; S Deo SV; Nilima N
J Cancer Res Ther; 2023; 19(2):312-320. PubMed ID: 37006068
[TBL] [Abstract][Full Text] [Related]
14. Inhibitor of apoptosis protein Livin promotes tumor progression and chemoradioresistance in human anaplastic thyroid cancer.
Kim HK; Kim SA; Jung EK; Lee KH; Lee JK; Kang HC; Joo YE; Lim SC; Yoon TM
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649820
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
[TBL] [Abstract][Full Text] [Related]
16. Case report: Complete response of an anaplastic thyroid carcinoma patient with
Gui L; Zhu Y; Li X; He X; Ma T; Cai Y; Liu S
Front Immunol; 2023; 14():1178682. PubMed ID: 37122752
[TBL] [Abstract][Full Text] [Related]
17. Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry.
Ahn J; Jin M; Song E; Ryu YM; Song DE; Kim SY; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Thyroid; 2021 Jan; 31(1):61-67. PubMed ID: 32611231
[No Abstract] [Full Text] [Related]
18. Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study.
Chintakuntlawar AV; Rumilla KM; Smith CY; Jenkins SM; Foote RL; Kasperbauer JL; Morris JC; Ryder M; Alsidawi S; Hilger C; Bible KC
J Clin Endocrinol Metab; 2017 Jun; 102(6):1943-1950. PubMed ID: 28324060
[TBL] [Abstract][Full Text] [Related]
19. PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.
Gray KD; McCloskey JE; Vedvyas Y; Kalloo OR; Eshaky SE; Yang Y; Shevlin E; Zaman M; Ullmann TM; Liang H; Stefanova D; Christos PJ; Scognamiglio T; Tassler AB; Zarnegar R; Fahey TJ; Jin MM; Min IM
Clin Cancer Res; 2020 Nov; 26(22):6003-6016. PubMed ID: 32887724
[TBL] [Abstract][Full Text] [Related]
20. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
Zhu X; Park S; Lee WK; Cheng SY
Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
